Integration of buprenorphine/naloxone treatment into HIV clinical care: Lessons from the BHIVES collaborative

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue SUPPL. 1, 2011, Pages

  Weiss, Linda ^a   Netherland, Julie ^a   Egan, James E ^a   Flanigan, Timothy P ^b   Fiellin, David A ^c   Finkelstein, Ruth ^a   Altice, Frederick L ^c  

^a NEW YORK ACADEMY OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; buprenorphine; health services research; heroin dependence; HIV; opioid related disorders

Indexed keywords

ANTIRETROVIRUS AGENT; BUPRENORPHINE PLUS NALOXONE;

ARTICLE; CLINICAL PRACTICE; COMMUNITY HOSPITAL; GENERAL PRACTITIONER; HEALTH CARE QUALITY; HEALTH PROGRAM; HEALTH SERVICE; HOSPITAL PERSONNEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; MEDICAL CARE; MENTAL HEALTH; OPIATE ADDICTION; PATIENT ATTITUDE; PATIENT CARE; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; PSYCHIATRY; SUBSTANCE ABUSE; URINALYSIS;

AMBULATORY CARE; ANTI-HIV AGENTS; BUPRENORPHINE; DELIVERY OF HEALTH CARE, INTEGRATED; HEALTH RESOURCES; HEALTH SERVICES NEEDS AND DEMAND; HIV INFECTIONS; HUMANS; NALOXONE; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PRIMARY HEALTH CARE; SUBSTANCE ABUSE TREATMENT CENTERS; UNITED STATES;

EID: 79951779992     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31820a8226     Document Type: Article

References (39)

1. Korthuis PT, Zephyrin LC, Fleishman JA, et al. Health-related quality of life in HIV-infected patients: the role of substance use. AIDS Patient Care STDS. 2008;22:859-867.
2. Hicks PL, Mulvey KP, Chander G, et al. The impact of illicit drug use and substance abuse treatment on adherence to HAART. AIDS Care. 2007;19: 1134-1140. (Pubitemid 350223192)
3. Rodriguez-Arenas MA, Jarrin I, del Amo J, et al. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain. AIDS Res Hum Retroviruses. 2006; 22:715-723. (Pubitemid 44734997)
4. Altice FL, Kamarulzaman A, Soriano VV, et al. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376:367-387.
5. Palepu A, Tyndall MW, Joy R, et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend. 2006; 84:188-194. (Pubitemid 44119095)
6. Saxon AJ, McCarty D. Challenges in the adoption of new pharmacother-apeutics for addiction to alcohol and other drugs. Pharmacol Ther. 2005; 108:119-128. (Pubitemid 41377124)
7. Johnson RE, Chutuape MA, Strain EC, et al. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000;343:1290-1297.
8. Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend. 2003;70:S59-S77. (Pubitemid 36556061)
9. Maremmani I, Pani PP, Pacini M, et al. Substance use and quality of life over 12 months among buprenorphine maintenance-treated and metha-done maintenance-treated heroin-addicted patients. J Subst Abuse Treat. 2007;33:91-98. (Pubitemid 350198612)
10. Jaffe JH, O'Keeffe C. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend. 2003;70:S3-S11. (Pubitemid 36556056)
11. Vastag B. In-office opiate treatment "not a panacea:" physicians slow to embrace therapeutic option. JAMA. 2009;290:731-734.
12. Turner BJ, Laine C, Lin YT, et al. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Arch Intern Med. 2005;165:1769-1776. (Pubitemid 41138966)
13. Sylla L, Bruce RD, Kamarulzaman A, et al. Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services. Int J Drug Policy. 2007;18:306-312. (Pubitemid 47126281)
14. Samet JH, Friedmann P, Saitz R. Benefits of linking primary medical care and substance abuse services: patient, provider, and societal perspectives. Arch Intern Med. 2001;161:85-91. (Pubitemid 32052147)
15. Institute of Medicine. Improving the Quality of Health Care for Mental and Substance-Use Conditions: Quality Chasm Series. Washington, DC: National Academy Press; 2006.
16. Health Management Associates. Integrating Publicly Funded Physical and Behavioral Health Services: A Description of Selected Initiatives. Lansing, MI: Health Management Associates, February 2007.
17. Gibson AE, Doran CM, Bell JR, et al. A comparison of buprenorphine treatment in clinic and primary care settings: a randomised trial. Med J Aust. 2003;179:38-42. (Pubitemid 36896192)
18. Miller NS, Sheppard LM, Colenda CC, et al. Why physicians are unprepared to treat patients who have alcohol- and drug-related disorders. Acad Med. 2001;76:410-418. (Pubitemid 32417323)
19. McMurphy S, Shea J, Switzer J, et al. Clinic-based treatment for opioid dependence: a qualitative inquiry. Am J Health Behav. 2006;30: 544-554. (Pubitemid 44358433)
20. Egan JE, Casadonte P, Gartenmann T, et al. The physician clinical support system-buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment. J Gen Intern Med. 2010;25:936-941.
21. Barry DT, Irwin KS, Jones ES, et al. Integrating buprenorphine treatment into office-based practice: a qualitative study. J Gen Intern Med. 2009;24: 218-225.
22. Basu S, Smith-Rohrberg D, Bruce RD, et al. Models for integrating buprenorphine therapy into the primary HIV care setting. Clin Infect Dis. 2006;42:716-721. (Pubitemid 43271389)
23. Netherland J, Botsko M, Egan JE, et al. Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat. 2009;36: 244-251.
24. Fiellin DA, O'Connor PG. Clinical practice. Office-based treatment of opioid-dependent patients. N Engl J Med. 2002;347:817-823. (Pubitemid 34988341)
25. Fiellin DA, O'Connor PG, Chawarski M, et al. Processes of care during a randomized trial of office-based treatment of opioid dependence in primary care. Am J Addict. 2004;13(Suppl 1):S67-S78. (Pubitemid 38585691)
26. Weiss L, Egan JE, Botsko M, et al, and BHIVES Collaborative. The BHIVES Collaborative: overview and organization of a multi-site demonstration of integrated buprenorphine and HIV treatment. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S7-S13.
27. Cheever L, Kresina TF, Cajina A, et al. A model federal collaborative to increase patient access to buprenorphine treatment in HIV primary care. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S3-S6.
28. Woolf SH. The meaning of translational research and why it matters. JAMA. 2008;299:211-213.
29. Green LW, Ottoson JM, Garcia C, et al. Diffusion theory, and knowledge dissemination, utilization, and integration in public health. Annu Rev Public Health. 2009;30:151-174.
30. Rogers E. Diffusion of Innovations. New York, NY: Free Press; 1995.
31. Sofaer S. Qualitative methods: what are they and why use them? Health Serv Res. 1999;34:1101-1118.
32. Sofaer S. Qualitative research methods. Int J Qual Health Care. 2002;14: 329-336.
33. Egan JE, Netherland J, Gass J, et al, and BHIVES Collaborative. Patient perspectives on buprenorphine/naloxone treatment in the context of HIV care. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S46-S53.
34. Chaudhry AA, Botsko M, Weiss L, et al, and BHIVES Collaborative. Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone (bup/nlx) and HIV care. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S14-S21.
35. Sullivan LE, Botsko M, Cunningham C, et al, and BHIVES Collaborative. The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S54-S61.
36. Lum PJ, Little S, Botsko M, et al, and BHIVES Collaborative. Opioid prescribing and provider confidence recognizing opioid abuse in HIV primary care settings. J Acquir Immune Defic Syndr. 2011;56(Suppl 1): S91-S97.
37. Finkelstein R, Netherland J, Sylla L, et al. Policy implications of integrating buprenorphine/naloxone treatment and HIV care. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S98-S104.
38. Fiellin DA, Sullivan LE, Egan JE, et al. Drug treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/nalox-one. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S33-S38.
39. Schackman BS, Leff J, Botsko M, et al, and BHIVES Collaborative. The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation. J Acquir Immune Defic Syndr. 2011; 56(Suppl 1):S76-S82.